CALEX Cap Device 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 BÜHLMANN Laboratories AG 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2017-03-20
  • 사례 출판 날짜
    2017-03-20
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: bühlmann laboratories ag calex cap device bühlmann laboratories ag has issued a medical device safety alert concerning its calex cap device [catalogue number: b-calex-c50, b-calex-c200, b-calex-c500]. according to the manufacturer, a mean positive bias of 15.6 % has been confirmed for results obtained with stool extraction using the original calex cap device in comparison to results obtained with the reference manual weighing and extraction method – 1:50 dilution. given the overall analytical and clinical performance of fecal calprotectin assays and the general imprecision level of stool extraction methods, the above mean bias of 15.6 % is considered to have limited impact on result interpretation. the positive bias may, in few cases, lead or have led to the interpretation of calprotectin levels as elevated (> 200 μg/g), requiring further investigative and curative procedures. with stool specimen preparation using the reference manual extraction procedure, they would be determined as having a low inflammatory response thus repeating the measurement and performing further investigations would be recommended. in few cases patients may be or may have been assigned as having a low inflammatory response (> 50μg/g), although, with stool specimen preparation using the reference manual extraction procedure, they would be determined as having normal calprotectin values. affected users are advised to the take the following actions:- when reviewing current calprotectin results obtained for stool specimens extracted with the original calex cap device (calex lots without “n”), consider the positive bias described above. a fast transition to the calex cap “n” device with high method agreement with the manual weighing and extraction – 1:50 dilution method is recommended. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 20 march 2017.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: BÜHLMANN Laboratories AG CALEX Cap Device
  • Manufacturer

Manufacturer